Role of Anti-platelet in Treatment of Acute Ischemic Stroke

NCT03266731 | Unknown

• 1 other identifier: ROAITOAIS
• Study Type: interventional
• Target: 120
• Locations: 0 countries
• Sites: N/A

Brief Summary

Role of anti-platelet in treatment of acute ischemic stroke to determine the safety of immediate anti-platelet therapy .that is started as soon as possible within the first 24 hours of the onset of symptoms.

Conditions

Stroke

Outcome Measures

Primary Outcomes (1)

• A clinically significant neurologic deterioration

  NIHSS score to detect the outcome of the patients as a greater than or equal to 2-point decrease or a score of 0.

  24 hours

Study Arms (1)

use of aspirin and clopidogrel

EXPERIMENTAL

Drug: Aspirin

Interventions

Aspirin DRUG

evaluates the safety and efficacy of clopidogrel and aspirin as an alternative treatment in patients not eligible for recombinant tissue plasminogen activator or any other acute reperfusion therapy with acute ischemic stroke (AIS) and transient ischemic attack (TIA) within 24 hours of symptoms onset

Also known as: clopidogrel

use of aspirin and clopidogrel

Eligibility Criteria

• Age: 40 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age of the patients is 40 years or older.
• Patients not eligible for recombinant tissue plasminogen activator or any other acute reperfusion therapy presenting after 6hours of onset of symptoms.
• Patients presented with clinical symptoms of acute stroke or TIA with onset less than 24 hours before starting any treatment.
• The diagnosis of stroke or TIA basing on clinical examination using National Institute of Health stroke scale (NIHSS) by a stroke specialist

You may not qualify if:

• Any history of ICH or systemic hemorrhage.
• Any evidence of hemorrhage on baseline CT brain imaging.
• Patients presented with failed medical or surgical thrombectomy.
• International normalized ratio (INR) more than 1.5.
• History of allergy to aspirin or clopidogrel or both of them.
• Platelets count less than 100,000/mm3.
• Hematocrit less than 30 mg/dL .
• glucose less than 50 mg/dL or greater than 400 mg/dL.to exclude hypoglycemia induced focal neurological deficit.

Sponsors & Collaborators

• Assiut University: lead

MeSH Terms

Conditions

Stroke

Interventions

Aspirin; Clopidogrel

Condition Hierarchy (Ancestors)

Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases

Intervention Hierarchy (Ancestors)

Salicylates; Hydroxybenzoates; Phenols; Benzene Derivatives; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals; Ticlopidine; Thienopyridines; Thiophenes; Sulfur Compounds; Pyridines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring

Central Study Contacts

hassan farweez, professor

CONTACT

01221741465; hassan.farwez@med.au.edu.eg

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: principal investigator

Study Record Dates

• First Submitted: August 28, 2017
• First Posted: August 30, 2017
• Study Start: January 4, 2018
• Primary Completion: January 4, 2019
• Study Completion: January 4, 2020
• Last Updated: August 31, 2017

Record last verified: 2017-08